Literature DB >> 17316053

20S proteasome and its inhibitors: crystallographic knowledge for drug development.

Ljudmila Borissenko1, Michael Groll.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17316053     DOI： 10.1021/cr0502504

Source DB:  PubMed          Journal:  Chem Rev        ISSN： 0009-2665            Impact factor:   60.622


× No keyword cloud information.
  116 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

Review 2.  Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.

Authors:  Min Shen; Tak Hang Chan; Q Ping Dou
Journal:  Anticancer Agents Med Chem       Date:  2012-10-01       Impact factor: 2.505

3.  Osmotic stress inhibits proteasome by p38 MAPK-dependent phosphorylation.

Authors:  Seung-Hoon Lee; Yoon Park; Sungjoo Kim Yoon; Jong-Bok Yoon
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

Review 4.  Lessons from the past and charting the future of marine natural products drug discovery and chemical biology.

Authors:  William H Gerwick; Bradley S Moore
Journal:  Chem Biol       Date:  2012-01-27

5.  Palau'amine and related oroidin alkaloids dibromophakellin and dibromophakellstatin inhibit the human 20S proteasome.

Authors:  Theresa A Lansdell; Nicole M Hewlett; Amanda P Skoumbourdis; Matthew D Fodor; Ian B Seiple; Shun Su; Phil S Baran; Ken S Feldman; Jetze J Tepe
Journal:  J Nat Prod       Date:  2012-05-16       Impact factor: 4.050

Review 6.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.

Authors:  Q Ping Dou; Jeffrey A Zonder
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

7.  Crossover inhibition as an indicator of convergent evolution of enzyme mechanisms: a β-lactamase and a N-terminal nucleophile hydrolase.

Authors:  S A Adediran; G Lin; R B Pelto; R F Pratt
Journal:  FEBS Lett       Date:  2012-10-23       Impact factor: 4.124

8.  Limitations of SLLVY-AMC in calpain and proteasome measurements.

Authors:  Christopher J Giguere; Rick G Schnellmann
Journal:  Biochem Biophys Res Commun       Date:  2008-05-05       Impact factor: 3.575

9.  Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.

Authors:  Boris Cvek; Vesna Milacic; Jan Taraba; Q Ping Dou
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

10.  Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.

Authors:  Daniela B B Trivella; Alban R Pereira; Martin L Stein; Yusuke Kasai; Tara Byrum; Frederick A Valeriote; Dean J Tantillo; Michael Groll; William H Gerwick; Bradley S Moore
Journal:  Chem Biol       Date:  2014-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.